collision metastasis of prostatic adenocarcinoma and urothelial carcinoma of the bladder

Clicks: 361
ID: 142480
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #13 of 60 articles by views in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The incidence of concomitant prostate adenocarcinoma found in patients with muscle-invasive bladder carcinoma is not uncommon, reaching up to 21%–28%. However, the presence of collision metastasis involving prostate cancer and bladder cancer within the same lymph node is exceedingly rare, with only 5 cases reported to date in the literature. We report a case of collision metastasis of prostate adenocarcinoma and urothelial carcinoma of the bladder in a 73-year-old man who underwent cystoprostatectomy with bilateral pelvic lymph node dissection for high-grade muscle-invasive urothelial carcinoma. Final pathology revealed a pT3aN2 high-grade urothelial carcinoma and pT3N1 Gleason 4 + 4 = 8 adenocarcinoma of the prostate with 12/40 pelvic lymph nodes positive for urothelial carcinoma. One node was positive for both urothelial carcinoma and prostate adenocarcinoma, confirmed by positive staining by p40 and prostate specific antigen(PSA), respectively. Immunohistochemistry is the sole method of confirming collision metastasis of two primary cancers. In this case, we describe immunohistochemical markers for urothelial carcinoma and prostate adenocarcinoma and their clinical implications. One month postoperatively, our patient began adjuvant leuprolide therapy and cycle 1 of gemcitabine and cisplatin chemotherapy, which he is tolerating well.
Reference Key
sellman2018urologycollision Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;David P Sellman;Leslie Peard;Greg Simpson;Katrina Lancaster;Sravan Kavuri;Martha Terris;Rabbi Madi
Journal European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Year 2018
DOI
10.4103/UA.UA_97_17
URL
http://www.urologyannals.com/article.asp?issn=0974-7796;year=2018;volume=10;issue=3;spage=342;epage=344;aulast=Sellman
Keywords
bladder cancer immunohistochemistry urology collision metastasis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.